Search

Your search keyword '"Loblaw A"' showing total 2,194 results

Search Constraints

Start Over You searched for: Author "Loblaw A" Remove constraint Author: "Loblaw A"
2,194 results on '"Loblaw A"'

Search Results

2. Elective pelvic nodal irradiation in the setting of ultrahypofractionated versus moderately hypofractionated and conventionally fractionated radiotherapy for prostate cancer: Outcomes from 3 prospective clinical trials

4. Developing and validating a simple urethra surrogate model to facilitate dosimetric analysis to predict genitourinary toxicity

5. Prostate high dose-rate brachytherapy as monotherapy for low and intermediate-risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy: A 9-year update

6. Elective pelvic nodal irradiation in the setting of ultrahypofractionated versus moderately hypofractionated and conventionally fractionated radiotherapy for prostate cancer: Outcomes from 3 prospective clinical trials

8. Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial

9. Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial

12. Randomized Trial of Concomitant Hypofractionated Intensity Modulated Radiation Therapy Boost Versus Conventionally Fractionated Intensity Modulated Radiation Therapy Boost for Localized High-Risk Prostate Cancer (pHART2-RCT)

14. Urethra contouring on computed tomography urethrogram versus magnetic resonance imaging for stereotactic body radiotherapy in prostate cancer

17. Genetic factors associated with prostate cancer conversion from active surveillance to treatment

20. Clinical implementation of magnetic resonance imaging simulation for radiation oncology planning: 5 year experience

22. Temporal Stability and Prognostic Biomarker Potential of the Prostate Cancer Urine miRNA Transcriptome

23. Cost-effectiveness of docetaxel in high-volume hormone-sensitive metastatic prostate cancer

24. Two-fraction stereotactic ablative radiotherapy with simultaneous boost to MRI-defined dominant intra-prostatic lesion – Results from the 2SMART phase 2 trial

26. Screening for prostate cancer: protocol for updating multiple systematic reviews to inform a Canadian Task Force on Preventive Health Care guideline update

27. Framework for Strengthening the Scholarship of Teaching and Learning in the Canadian College Sector

30. Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial

32. Development and dissemination of structured hashtags for radiation oncology: Two-Year trends

33. Screening for prostate cancer: protocol for updating multiple systematic reviews to inform a Canadian Task Force on Preventive Health Care guideline update

34. A political economy of TVET professionalisation : a case study of chefs at a Canadian polytechnic

38. Defining radio-recurrent intra-prostatic target volumes using PSMA-targeted PET/CT and multi-parametric MRI

39. Delivery of Virtual Care in Oncology: Province-Wide Interprofessional Consensus Statements Using a Modified Delphi Process

41. Brachytherapy for high grade prostate cancer induces distinct changes in circulating CD4 and CD8 T cells – Implications for systemic control

44. Stereotactic Body Radiotherapy for High-Risk Localized Carcinoma of the Prostate (SHARP) Consortium: Analysis of 344 Prospectively Treated Patients

45. Long non-coding RNA urothelial carcinoma associated 1 (UCA1) mediates radiation response in prostate cancer

46. Long non-coding RNA urothelial carcinoma associated 1 (UCA1) mediates radiation response in prostate cancer.

47. Stereotactic Body Radiotherapy: Hitting Harder, Faster, and Smarter in High-Risk Prostate Cancer

50. Outcomes of Urinary Tract Infection Management by Pharmacists (RxOUTMAP)

Catalog

Books, media, physical & digital resources